Edwards Lifesciences announced it has entered into an agreement to acquire JenaValve

image credit- shutterstock

Peijia Medical Limited, a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, commented on the expected acquisition of JenaValve Technology,an exclusive technology licensing partner of Peijia, by Edwards Lifesciences.

On July 24, 2024, Edwards announced that it had entered into an agreement to acquire JenaValve, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is currently untreated today. JenaValve presented positive results of its U.S. pivotal trial for the treatment of symptomatic, severe AR in high-risk patients late last year. Edwards will accelerate development of this novel technology with the goal to enable earlier patient access. Edwards anticipates U.S. Food and Drug Administration (FDA) approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR.